Want to see IN:NEULANDLAB full AI Analyst Report?
NEULANDLAB Stock Chart & Stats
₹18570.85
₹448.00(2.42%)
At close: 4:00 PM EDT
₹18570.85
₹448.00(2.42%)
Day’s Range― - ―
52-Week Range₹11,500.00 - ₹24,235.05
Previous CloseN/A
Volume27.75K
Average Volume (3M)3.83K
Market Cap
₹267.89B
Enterprise Value₹153.58B
Total Cash (Recent Filing)₹766.70M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)53.8
Beta1.32
Next Earnings
Nov 05, 2026EPS Estimate
33.84Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)387.97
Shares Outstanding12,829,889
10 Day Avg. Volume7,314
30 Day Avg. Volume3,829
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)8.23
Price to Sales (P/S)7.63
P/FCF Ratio-262.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)368.61
Revenue Forecast (FY)₹24.32B
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilitySustained high net and operating margins indicate that Neuland’s API and custom manufacturing activities generate meaningful economic value. This profitability provides internal funding capacity, supports resilience through normal industry cycles, and can strengthen the company’s ability to reinvest in complex chemistry capabilities.
Conservative LeverageA low-leverage balance sheet reduces financial pressure and preserves flexibility to invest in capacity, development, or working capital. Steady equity growth and strong historical returns on equity also support the view that the business has built a durable financial base rather than relying heavily on debt.
Strong Earnings GrowthThe reported combination of strong revenue growth and much faster earnings growth points to substantial recent operating expansion and improved earnings power. If the company sustains demand for its APIs and custom manufacturing services, this growth can reinforce scale, customer relationships, and reinvestment capacity.
Bears Say
Negative Free Cash FlowNegative free cash flow reduces near-term financial flexibility even when accounting profits are strong. The shift may reflect higher investment or working-capital needs, but it means more cash is being absorbed by operations and expansion, potentially limiting internally funded growth if the pattern persists.
Margin CompressionA sharp gross-margin decline can weaken the earnings economics of API and custom manufacturing sales, even when revenue grows strongly. If higher input costs or an unfavorable product mix continue, operating leverage may become less beneficial and reported profit growth could prove less durable.
Higher Absolute DebtAlthough leverage remains low, rising absolute debt introduces an additional claim on future cash generation and modestly reduces balance-sheet flexibility. Combined with compressed margins and negative free cash flow, further debt growth could constrain investment choices or increase execution sensitivity.
Neuland Laboratories Ltd. News
NEULANDLAB FAQ
What was Neuland Laboratories Ltd.’s price range in the past 12 months?
Neuland Laboratories Ltd. lowest stock price was ₹11500.00 and its highest was ₹24235.05 in the past 12 months.
What is Neuland Laboratories Ltd.’s market cap?
Neuland Laboratories Ltd.’s market cap is ₹267.89B.
When is Neuland Laboratories Ltd.’s upcoming earnings report date?
Neuland Laboratories Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 24 days.
How were Neuland Laboratories Ltd.’s earnings last quarter?
Neuland Laboratories Ltd. released its earnings results on Aug 05, 2026. The company reported ₹115 earnings per share for the quarter, beating the consensus estimate of ₹60.01 by ₹54.99.
Is Neuland Laboratories Ltd. overvalued?
According to Wall Street analysts Neuland Laboratories Ltd.’s price is currently Overvalued.
Does Neuland Laboratories Ltd. pay dividends?
Neuland Laboratories Ltd. pays a Annually dividend of ₹34 which represents an annual dividend yield of 0.16%. See more information on Neuland Laboratories Ltd. dividends here
What is Neuland Laboratories Ltd.’s EPS estimate?
Neuland Laboratories Ltd.’s EPS estimate is 33.84.
How many shares outstanding does Neuland Laboratories Ltd. have?
Neuland Laboratories Ltd. has 12,829,889 shares outstanding.
What happened to Neuland Laboratories Ltd.’s price movement after its last earnings report?
Neuland Laboratories Ltd. reported an EPS of ₹115 in its last earnings report, beating expectations of ₹60.01. Following the earnings report the stock price went up 3.507%.
Which hedge fund is a major shareholder of Neuland Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:NEULANDLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neuland Laboratories Ltd.
Neuland Laboratories Ltd. operates as a global developer and supplier of active pharmaceutical ingredients (APIs), distributing its products across India, Europe, the United States, and other international markets. These APIs are crucial components in treatments spanning a wide array of therapeutic areas, such as respiratory conditions (antiasthmatics), cardiovascular health, fungal infections, seizure control (anticonvulsants), central nervous system disorders, bacterial infections (fluoroquinolones, antibacterial), mental health (antipsychotic), and Parkinson's disease. Additionally, the company provides bespoke manufacturing solutions and specialized peptide synthesis services. Founded in 1984, Neuland Laboratories is headquartered in Hyderabad, India.
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Glenmark Life Sciences Limited
―
Granules India Limited
―
Laurus Labs Ltd.
―